Vanguard Group
REVB icon

Vanguard Group’s Revelation Biosciences REVB Stock Holding History

Vanguard Group’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$42K Buy
+13,126
New +$57.4K ﹤0.01% 4260

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group's REVB Position: Q4 2025 in Review

Vanguard Group opened a new position in Revelation Biosciences (REVB) in Q4 2025: 13,126 shares worth $42K. The stake represents ﹤0.01% of the portfolio and ranks #4260 among its holdings.

13 funds tracked by Wall St. Rank hold REVB as of Q4 2025.

  • Vanguard Group held 13,126 shares of Revelation Biosciences worth $42K as of Q4 2025.
  • Revelation Biosciences was a new Vanguard Group position in Q4 2025.
  • Revelation Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4260 holding.
  • 13 funds tracked by Wall St. Rank held Revelation Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.